MOTS-c: how to inject it, reconstitution, and injection sites

Last updated 2026-07-24

Is there an FDA-approved way to inject MOTS-c?

No. Search Drugs@FDA, the FDA's own database of approved drug products, and MOTS-c doesn't appear ^[1]. There's no approved injectable formulation, no approved dose, no approved needle gauge, none of it. Everything you read about injecting MOTS-c, including this article, is extrapolated from animal studies, cell studies, and general peptide-handling practice, not from an FDA-reviewed clinical protocol. That matters more than it sounds like. When a drug is approved, the dose, injection site, and schedule come from human trials designed to find the smallest effective dose with the fewest side effects. None of that work has been done and published for MOTS-c in humans. What follows is a description of common practice among people using compounded MOTS-c, not a guideline anyone has proven safe or effective at a population level. MOTS-c is also on FDA's radar in the bulk drug substance sense: the agency's 503A bulks list ^[2] and 503B bulks list ^[3] are the mechanisms through which compounding pharmacies could gain a legal pathway to prepare a substance, and MOTS-c's status on those lists changes over time. Check FDA's current nomination list ^[4] before assuming anything about legal compounding status; it moves.

How is MOTS-c usually reconstituted before injection?

MOTS-c ships as a lyophilized (freeze-dried) powder in a sealed vial, and it needs to be reconstituted with bacteriostatic water or sterile water before it can go into a syringe. The peptide itself doesn't come pre-mixed. This is standard for essentially all injectable peptides sold through compounding channels, not something specific to MOTS-c. The general technique: swab the vial top with an alcohol wipe, draw the diluent into a syringe, and inject it slowly down the inside wall of the vial rather than directly onto the powder (a hard stream can shear the peptide and reduce yield). Swirl gently, don't shake. Shaking creates foam and can denature proteins through mechanical stress at the air-liquid interface. Once reconstituted, peptides are fragile. Refrigerate at 2-8°C (36-46°F) and most compounders will tell you to use the vial within 2 to 4 weeks, though nobody has published stability data specific to reconstituted MOTS-c at various temperatures and diluent volumes. That's a real gap. Bacteriostatic water (with 0.9% benzyl alcohol) is generally preferred over plain sterile water for multi-dose vials because the preservative slows microbial growth across repeated draws over days or weeks.

What injection sites and technique do people use for MOTS-c?

Subcutaneous injection, the same basic technique used for insulin, is what's described in essentially every account of MOTS-c self-administration. That means injecting into the fat layer just under the skin, not into muscle. Common sites are the abdomen (at least 2 inches from the navel), the front of the thigh, or the back of the upper arm. A typical subcutaneous injection uses an insulin syringe with a short, fine needle (commonly 29 to 31 gauge, 4 to 6mm long). Pinch a fold of skin, insert the needle at roughly 45 to 90 degrees depending on the fold thickness, inject slowly, and hold for a few seconds before withdrawing. Rotate sites between injections; using the same quarter-inch of skin every day for weeks is a fast way to get lumps, bruising, or localized fat changes (lipohypertrophy), a known issue with repeated insulin injections in the same spot. None of this technique is MOTS-c specific. It's generic subcutaneous injection practice borrowed from decades of diabetes care, applied to a peptide that hasn't been through the same clinical vetting. For a broader look at how these injections are typically structured, see our MOTS-c peptide injection guide.

What dose of MOTS-c do people actually use, and where does that number come from?

There's no clinically established human dose. Full stop. The Cell Metabolism paper that first characterized MOTS-c's metabolic effects, showing it promotes metabolic homeostasis and reduces obesity and insulin resistance, was done in mice, dosed by body weight in a controlled lab setting, not in people self-administering at home ^[5]. Doses circulating in compounding and self-experimentation communities (commonly discussed in the 5 to 10mg per week range, split across 2 to 3 injections) are not derived from a published human pharmacokinetic study. They appear to be back-calculated, loosely, from animal dosing and adjusted downward by guesswork. That's a meaningfully different thing from an FDA-reviewed dose-finding trial. If you want the fuller breakdown of how those numbers get thrown around and what a more conservative approach looks like, our MOTS-c dosage article covers it, and the MOTS-c 10mg dosage calculator walks through the reconstitution math if you're trying to figure out concentration per unit volume. A calculator can get your dilution math right. It cannot tell you whether the dose is correct, because nobody knows that yet.

What time of day should MOTS-c be injected?

There's no clinical trial data on injection timing for MOTS-c in humans, so anything said here is inference from mechanism, not instruction. The 2018 Cell Metabolism paper showing MOTS-c translocates to the nucleus under metabolic stress to regulate gene expression ^[6] suggests the peptide's activity is tied to metabolic state (exercise, fasting, energy stress) rather than a fixed clock time. Some people inject before a workout on the theory that MOTS-c's AMPK-linked signaling overlaps with exercise-induced stress responses; a 2022 review in Diabetes & Metabolism Journal on exercise, mitohormesis, and MOTS-c lays out that mechanistic overlap ^[7]. That's a plausible rationale for timing around exercise. It is not evidence that pre-workout injection produces a better outcome than any other timing, because that comparison hasn't been run in humans. Morning versus evening, fasted versus fed: pick a time you'll actually remember and stay consistent with it. Consistency probably matters more than the specific hour, if only because missed or erratic dosing makes any effect (real or imagined) harder to track.

How many injections per week, and for how long?

Protocols described in compounding and self-experimentation circles typically run 5 to 6 days per week for cycles of 4 to 8 weeks, sometimes with weeks off in between. None of that cadence comes from a published human trial. It is community convention, and it varies a fair amount from source to source, which itself is a signal that nobody has nailed down an optimal schedule. The mouse work that anchors most of the excitement around MOTS-c used repeated dosing over weeks to see metabolic effects ^[5], but translating a rodent dosing schedule to a human one requires assumptions about clearance rate, body surface area scaling, and receptor biology that haven't been validated in people. A 2023 review in Frontiers in Endocrinology calling MOTS-c 'a promising mitochondrial-derived peptide for therapeutic exploitation' ^[8] is explicit that this is still exploratory, preclinical-stage science, not a settled clinical regimen. If you're going to use it, shorter cycles with clear stop points, rather than indefinite daily use, is the more conservative posture, if only because there's no long-term human safety data to justify continuous use.

Does MOTS-c actually work like 'exercise in a pill'?

That phrase is marketing shorthand, not a research finding, and it oversimplifies what the studies show. MOTS-c circulates in the body and, in mice, its levels change with exercise, which is where the 'exercise mimetic' idea comes from. But 'associated with exercise' and 'substitutes for exercise' are very different claims, and the second one hasn't been demonstrated in humans. What's actually been shown: in a 2015 Cell Metabolism study, MOTS-c administration reduced diet-induced obesity and improved insulin sensitivity in mice ^[5]. A 2021 study in the same journal found MOTS-c reduces myostatin and muscle atrophy signaling, again in an animal/cell model ^[9]. A 2024 iScience paper found MOTS-c binds and activates CK2 to modulate skeletal muscle function ^[10]. A 2021 review in Biochimica et Biophysica Acta specifically on mitochondrial-derived peptides and exercise lays out the mechanistic case for MOTS-c as part of the exercise-response signaling network ^[11], and a 2022 Diabetes & Metabolism Journal review frames MOTS-c within 'mitohormesis,' the idea that mild mitochondrial stress (like exercise) triggers adaptive signaling ^[7]. None of that is a human trial showing MOTS-c injections replace a training program. It's a plausible, interesting mechanistic story built almost entirely on rodent and cell data. Calling it 'exercise in a pill' skips past that gap. If you're reading this looking for the honest state of the underlying science, our MOTS-c evidence overview goes through the full body of work section by section.

What are the injection site reactions and side effects to expect?

Because there's no completed human trial program for MOTS-c, there's no FDA-reviewed side effect profile to point to; what exists is inference from general subcutaneous peptide injection experience and from the compound classes MOTS-c gets grouped with. A 2026 Sports Medicine review on the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance is a useful read here precisely because it treats unapproved peptides, including compounds like MOTS-c, as a category with unresolved safety questions rather than individually vetted products ^[12]. Locally, expect the standard subcutaneous injection reactions: redness, mild swelling, itching, or a small bruise at the site, usually resolving within a day or two. Rotating sites (as covered above) reduces the risk of lumps and lipohypertrophy from repeated injection in the same spot. Systemically, there is essentially no published human adverse event data specific to MOTS-c to draw from. That's the honest answer. It's not that MOTS-c has been shown safe; it's that it hasn't been through the kind of trial that would surface rare or long-term risks either way. For a fuller rundown of what's known and unknown on the safety side, see MOTS-c side effects.

Is compounded MOTS-c legal to buy and inject?

This is genuinely complicated and depends on regulatory categories that shift. Under 21 U.S.C. 353a ^[13], licensed pharmacies can compound drugs from bulk substances under specific conditions, but only substances on FDA's approved bulks lists, 21 CFR 216.23 for 503A pharmacies ^[2] and 21 CFR 216.24 for 503B outsourcing facilities ^[3], qualify without additional restriction. FDA maintains a running list of substances nominated for compounding consideration ^[4], and where MOTS-c sits on that list at any given moment determines a lot about the legal footing of a compounded product. Separately, FDA's own guidance on bulk drug substances used in compounding under Section 503A ^[14] lays out the criteria the agency uses to evaluate nominated substances, including whether there's a clinical need and whether the substance has a history of safe use. MOTS-c, being a research peptide with a thin human safety record, doesn't cleanly satisfy that second criterion the way a long-marketed drug would. FDA's definition of 'intended use,' at 21 CFR 201.128 ^[15], is also relevant to how MOTS-c gets marketed: labeling and marketing claims (cognitive benefits, anti-aging claims, disease treatment claims) can shift a product's regulatory status even if the underlying substance is the same. This is part of why reputable sources stick to describing mechanism and animal/cell data rather than promising outcomes. If you're weighing where to source a compounded product, our MOTS-c peptide buy guide covers what to look for in a compounding pharmacy's documentation and testing.

What does the broader research on MOTS-c actually cover, beyond metabolism?

The mechanistic story around MOTS-c has grown well past the original metabolic finding, and it's worth knowing the range because it shows both how interesting the biology is and how far most of it is from a human injection protocol. On muscle specifically: a 2022 Peptides study found MOTS-c promotes muscle differentiation in vitro (in cell culture) ^[16]. A 2024 American Journal of Physiology paper found MOTS-c attenuates immobilization-induced skeletal muscle atrophy in an animal model by suppressing lipid infiltration ^[17]. On bone: a 2023 Frontiers in Physiology review covers MOTS-c's role in bone metabolism regulation ^[18]. On cartilage: a 2025 Free Radical Biology & Medicine paper found MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism ^[19]. Outside the musculoskeletal system, the range is wider still: a 2024 Gut paper found a novel antiviral role for MOTS-c during hepatitis B infection via mitochondrial remodeling ^[20]; a 2024 Advanced Science paper found MOTS-c suppresses ovarian cancer progression in a lab model ^[21]; a 2022 Pharmacological Research study found MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes model ^[22]; and a 2025 Scientific Reports paper found MOTS-c mimics exercise signaling to combat diabetic liver fibrosis in a rodent model by targeting the Keap1-Nrf2-Smad2/3 pathway ^[23]. Every one of these is animal or cell-culture work. That's not a knock on the science, it's the necessary caveat: interesting mechanism, thin translation to human dosing decisions.

What should someone actually do before injecting MOTS-c?

Talk to a physician who knows your health history, ideally one experienced with peptide therapies, before starting anything. That's not boilerplate advice here; it matters more than usual precisely because there's no approved product, no approved dose, and no long-term human safety data to lean on if something goes wrong. Check sourcing carefully. A compounding pharmacy operating under Section 503A ^[13] should be licensed in your state and able to provide a Certificate of Analysis confirming purity and identity for the specific lot you're buying. If a seller can't produce that, that's a hard stop, not a negotiating point. At MOTS-c Co, we point people toward the provider-reviewed pathway rather than gray-market vials with no chain of custody: a treatment plan reviewed by a licensed clinician, filled through Tailor Made Compounding, a licensed 503A pharmacy, rather than sourced from an unregulated online seller with no traceable testing. That's a sourcing and oversight choice, not a claim that this makes MOTS-c's underlying evidence base any stronger than what's described above. Whatever route you take, keep records: lot numbers, reconstitution dates, dose, injection site, and anything you notice, good or bad. If the human evidence catches up to the animal data someday, it'll be because people tracked what actually happened, not because a compounding vial worked exactly like the mouse study implied it would.

Frequently asked questions

How do you reconstitute MOTS-c powder for injection?

Swab the vial, draw bacteriostatic or sterile water into a syringe, and inject it slowly down the inside wall of the vial rather than directly onto the powder. Swirl gently, don't shake, and let it fully dissolve before drawing a dose. Refrigerate afterward. There's no published human stability study specific to reconstituted MOTS-c, so most guidance borrows from general peptide handling practice.

What size needle is used for MOTS-c injections?

People typically use insulin syringes with 29 to 31 gauge needles, 4 to 6mm long, for subcutaneous injection. This is standard for most self-administered peptides, not something validated specifically for MOTS-c in a clinical trial.

Where on the body do you inject MOTS-c?

Common subcutaneous sites are the abdomen (at least 2 inches from the navel), the front of the thigh, and the back of the upper arm. Rotate sites between injections to avoid lumps, bruising, or lipohypertrophy from repeated use of the same spot.

What is the typical MOTS-c dosage per injection?

There's no FDA-approved or clinically validated human dose. Compounding and self-experimentation sources commonly describe totals in the 5 to 10mg per week range split across several injections, but that figure is extrapolated from animal dosing, not derived from a published human trial.

Is MOTS-c FDA approved?

No. A search of Drugs@FDA, the FDA's database of approved drug products, shows no approved MOTS-c product. Its regulatory status runs instead through the bulk drug substance compounding framework under 21 U.S.C. 353a, and its status on FDA's bulks lists can change over time.

Is MOTS-c legal to buy from a compounding pharmacy?

It depends on current regulatory status. Licensed 503A pharmacies compound from FDA's approved bulks list under 21 CFR 216.23, and 503B outsourcing facilities work from a separate list under 21 CFR 216.24. Check FDA's current nominated substances list before assuming legal status, because it shifts.

Does MOTS-c actually work like exercise in a pill?

That's marketing language, not a finding. MOTS-c levels change with exercise in animal studies and it shares signaling pathways with exercise-induced mitochondrial stress responses (mitohormesis), but no human trial has shown injected MOTS-c substitutes for exercise. The claim outruns the evidence.

What are the side effects of injecting MOTS-c?

Locally, expect standard subcutaneous injection reactions: redness, mild swelling, or bruising, usually resolving within a day or two. There's no published human trial data on systemic side effects specific to MOTS-c, which is itself the key caveat, not evidence of safety.

How often should MOTS-c be injected?

Protocols described in compounding circles run 5 to 6 days per week for 4 to 8 week cycles, but this schedule comes from community convention and rodent dosing extrapolation, not a published human trial. Nobody has established an optimal frequency.

Can MOTS-c help with muscle loss or atrophy?

Animal and cell studies suggest a mechanism: a 2021 study found MOTS-c reduces myostatin and muscle atrophy signaling, and a 2024 study found it attenuates immobilization-induced muscle atrophy in an animal model by suppressing lipid infiltration. Neither is a human clinical trial, so translation to people is not established.

What time of day is best to inject MOTS-c?

There's no human trial comparing injection timing. Some people inject before exercise based on mechanistic overlap between MOTS-c signaling and exercise-induced stress responses, but this is inference, not demonstrated advantage. Consistency in timing likely matters more than the specific hour chosen.

Do I need a prescription to get MOTS-c?

Through the legitimate compounding pathway, yes: a licensed clinician evaluates you and a prescription is filled by a licensed 503A pharmacy. Vials sold online without any clinical oversight or Certificate of Analysis sit outside that system entirely and carry higher risk with no traceability.

Sources

1. FDA, Drugs@FDA approved drug products database: No FDA-approved MOTS-c drug product exists in the agency's approved drug database
2. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances list that licensed 503A pharmacies may compound from
3. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list that 503B outsourcing facilities may compound from
4. FDA, bulk drug substances nominated for use in compounding (current list): FDA maintains a current, changing list of substances nominated for compounding consideration
5. Cell Metabolism, 2015 (PMID 25738459): MOTS-c administration reduced diet-induced obesity and improved insulin resistance in mice
6. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate gene expression in response to metabolic stress
7. Diabetes & Metabolism Journal, 2022 (PMID 35656563): Reviews MOTS-c's mechanistic role in mitohormesis and exercise-linked signaling
8. Frontiers in Endocrinology, 2023 (PMID 36761202): Describes MOTS-c as a promising peptide for therapeutic exploitation, signaling its exploratory stage
9. American Journal of Physiology: Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in an animal/cell model
10. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
11. Biochimica et Biophysica Acta: General Subjects, 2021 (PMID 34520826): Reviews the mechanistic link between mitochondrial-derived peptides including MOTS-c and exercise
12. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy questions for approved and unapproved peptide therapies used in athletic performance
13. Cornell Legal Information Institute, 21 U.S.C. 353a: Establishes the statutory framework under which licensed pharmacies may compound drugs from bulk substances
14. FDA, bulk drug substances used in compounding under section 503A: Lays out FDA's criteria for evaluating nominated bulk substances, including clinical need and history of safe use
15. eCFR, 21 CFR 201.128: Defines how marketing and labeling claims determine a product's regulatory intended use
16. Peptides, 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in an in vitro cell culture model
17. American Journal of Physiology: Endocrinology and Metabolism, 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy in an animal model by suppressing lipid infiltration
18. Frontiers in Physiology, 2023 (PMID 37200834): Reviews MOTS-c's role in regulating bone metabolism
19. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model
20. Gut, 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection via mitochondrial remodeling
21. Advanced Science, 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression in a lab model by attenuating USP7-mediated LARS1 deubiquitination
22. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes model
23. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimics exercise signaling to combat diabetic liver fibrosis in a rodent model via Keap1-Nrf2-Smad2/3